Ph1 Industry Pvt Ltd

Ph1 Industry Pvt Ltd company information, Employees & Contact Information

PH1 Industries is an Engineering and Technology services company which has vast experience in the field of Alternate Fuel Feeding Systems – Liquids & Solids, Emission Control Systems, Bulk Materials handling (Equipments as well as complete System), Injection Skids, etc for Cements, Pharma & Chemicals, Oil & Gas, Power Industries. PH1 has proven capabilities and experience with highly qualified engineers and designers working in our group. With over a decade of experience, we have done, and often exceeded, our client’s expectations. With customer satisfaction as our goal, we develop custom built systems and provide services to meet client’s and operational constraints. Herewith are furnishing the list of Systems and Products offered by PH1 for your kind reference : A. BULK MATERIAL HANDLING SYSTEMS 1. Fly Ash conveying system 2. Coal Handling system 3. Pneumatic Conveying system(Dense phase & Lean phase) 4. Bulk Loading Systems 5. Bulker Unloading system 6. Silo Aeration & Extraction Systems B. EMISSION CONTROL SYSTEMS 1. NOx Reduction System – SNCR 2. Bag Filters 2.1 Pulse Jet Bag Filter 2.2 Reverse Air Bag House C. IN-PLANT HANDLING EQUIPMENTS  Screw Conveyors  Drag Chain Conveyors  Apron Feeders  Air slides  Rotary Airlocks  Slide Gates  Divertor Gates  Dosing valves  Flap Valves  Dampers We at PH1 are specialised in resolving the issues related to Bagfilter like high DP, shorter bag life, Corrosion, High emission etc., & Also Clinker Tunnel conveying De-dusting systems.

Company Details

Employees
51
Address
No. 13-58, Indiragandhi Nagar,, Hmt Road,balanagar,india
Industry
Industrial Machinery Manufacturing
NAICS
Industrial Machinery Manufacturing
Food Product Machinery Manufacturing
Semiconductor Machinery Manufacturing
Sawmill, Woodworking, and Paper Machinery Manufacturing
Printing Machinery and Equipment Manufacturing
Other Industrial Machinery Manufacturing
Website
ph1.in
HQ
Hyderabad, Telangana
Looking for a particular Ph1 Industry Pvt Ltd employee's phone or email?

Ph1 Industry Pvt Ltd Questions

News

Lumasiran for PH1 in Infants and Young Children - Docwire News

Lumasiran for PH1 in Infants and Young Children Docwire News

Sino is up next in CDH17 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Sino is up next in CDH17 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients - Yahoo! Finance Canada

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients Yahoo! Finance Canada

60-Month Results for Lumasiran in PH1 - Docwire News

60-Month Results for Lumasiran in PH1 Docwire News

Anocca steps into a KRAS battle | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Anocca steps into a KRAS battle | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

C4 takes the Ikaros/Aiolos battle to Bristol | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

C4 takes the Ikaros/Aiolos battle to Bristol | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3 - ScienceDirect.com

Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3 ScienceDirect.com

Story of Discovery: The NIDDK provides foundational research support for first FDA-approved therapy to treat the metabolic disease primary hyperoxaluria type 1 - National Institutes of Health (.gov)

Story of Discovery: The NIDDK provides foundational research support for first FDA-approved therapy to treat the metabolic disease primary hyperoxaluria type 1 National Institutes of Health (.gov)

Werner not good enough for Roche | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Werner not good enough for Roche | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Actithera hopes to do FAP differently | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Actithera hopes to do FAP differently | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR 2025 preview – distressed biotechs seek redemption | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AACR 2025 preview – distressed biotechs seek redemption | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

RemeGen cools on DR5 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

RemeGen cools on DR5 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Take five in T-cell lymphoma | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Take five in T-cell lymphoma | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Early-stage changes at Roche | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Early-stage changes at Roche | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO-GI – Inhibrx presses ahead with DR5 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO-GI – Inhibrx presses ahead with DR5 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Two more reasons for GSK to be wary of Tim-3 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Two more reasons for GSK to be wary of Tim-3 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

CytomX shifts towards EpCAM | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CytomX shifts towards EpCAM | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Nuvectis switches focus | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Nuvectis switches focus | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Elevation goes down on Claudin disaster | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Elevation goes down on Claudin disaster | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope - Nature

Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope Nature

After zolbetuximab investors look for a Claudin18.2 encore | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

After zolbetuximab investors look for a Claudin18.2 encore | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

What now for NK-cell engagers? | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

What now for NK-cell engagers? | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Xencor “still committed” to oncology | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Xencor “still committed” to oncology | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Incyte swings the axe on oral checkpoint inhibitors | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Incyte swings the axe on oral checkpoint inhibitors | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

A cancer pipeline cull from AbbVie | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

A cancer pipeline cull from AbbVie | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

US clears Novo Nordisk's Rivfloza for primary hyperoxaluria type 1 - FirstWord Pharma

US clears Novo Nordisk's Rivfloza for primary hyperoxaluria type 1 FirstWord Pharma

Merck and Daiichi team up again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Merck and Daiichi team up again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR 2024 preview – more companies pile into popular mechanisms | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AACR 2024 preview – more companies pile into popular mechanisms | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 – Astra’s B7-H4 effort underwhelms | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2024 – Astra’s B7-H4 effort underwhelms | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR 2025 – Roche sets a bar in Werner helicase inhibition | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AACR 2025 – Roche sets a bar in Werner helicase inhibition | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Jazz joins the KRAS band with Redx deal | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Jazz joins the KRAS band with Redx deal | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Amgen packs up in Claudin6 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Amgen packs up in Claudin6 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASH 2023 – lupus target could work in lymphoma too | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASH 2023 – lupus target could work in lymphoma too | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

The SHP2 ship sails | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

The SHP2 ship sails | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Ipsen finds a MAIT in Biomunex | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Ipsen finds a MAIT in Biomunex | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

First phase 1 starters challenge Pluvicto and Revolution | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

First phase 1 starters challenge Pluvicto and Revolution | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO 2025 preview – Merus tops Bicara | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 preview – Merus tops Bicara | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Amgen pushes on in Steap1 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Amgen pushes on in Steap1 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Pfizer isn’t done with CD47 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Pfizer isn’t done with CD47 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

The end of Exkivity is another win for Rybrevant | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

The end of Exkivity is another win for Rybrevant | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

CD19 is worth $700m to Merck | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CD19 is worth $700m to Merck | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Three more Pfizer oncology projects go in latest cull | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Three more Pfizer oncology projects go in latest cull | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Just how independent is Genentech? | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Just how independent is Genentech? | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Sanofi switches to another CEACAM5 asset | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Sanofi switches to another CEACAM5 asset | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Arcus gets anti-CD73 small molecule buy-in | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Arcus gets anti-CD73 small molecule buy-in | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO-GU – subcutaneous Opdivo puts the pressure on Merck | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO-GU – subcutaneous Opdivo puts the pressure on Merck | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

First treatment for rare condition primary hyperoxaluria type 1 - European Medicines Agency

First treatment for rare condition primary hyperoxaluria type 1 European Medicines Agency

Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males - Cureus

Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males Cureus

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer - Yahoo Finance

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer Yahoo Finance

Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal - Fierce Biotech

Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal Fierce Biotech

Revolution in the next KRAS battleground | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Revolution in the next KRAS battleground | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Arbor’s ABO-101 awarded US orphan drug designation for primary hyperoxaluria type 1 - BioWorld MedTech

Arbor’s ABO-101 awarded US orphan drug designation for primary hyperoxaluria type 1 BioWorld MedTech

Megawide's PH1 to unveil low-cost mid-rise housing - Philstar.com

Megawide's PH1 to unveil low-cost mid-rise housing Philstar.com

No giving up on ROR1 for Oncternal | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

No giving up on ROR1 for Oncternal | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Nothing like Hippo for cooling investor enthusiasm | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Nothing like Hippo for cooling investor enthusiasm | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

A novel nonsense variant of the AGXT identified in a Chinese family: special variant research in the Chinese reference genome - BMC Nephrology

A novel nonsense variant of the AGXT identified in a Chinese family: special variant research in the Chinese reference genome BMC Nephrology

Three mystery phase 1 entrants | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Three mystery phase 1 entrants | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients - Business Wire

Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients Business Wire

Two novel AGXT mutations identified in primary hyperoxaluria type-1 and distinct morphological and structural difference in kidney stones - Nature

Two novel AGXT mutations identified in primary hyperoxaluria type-1 and distinct morphological and structural difference in kidney stones Nature

Alnylam makes rare disease education accessible to kids with animated videos - Medical Marketing and Media

Alnylam makes rare disease education accessible to kids with animated videos Medical Marketing and Media

Alnylam debuts video series to help kids understand rare disease PH1 - Fierce Pharma

Alnylam debuts video series to help kids understand rare disease PH1 Fierce Pharma

Kwumsy Power Hub PH1 with 65 W GaN charger and 4K HDMI ports unveiled - Notebookcheck

Kwumsy Power Hub PH1 with 65 W GaN charger and 4K HDMI ports unveiled Notebookcheck

PH1 eyes disruption through ‘First World’ experience - BusinessWorld - BusinessWorld Online

PH1 eyes disruption through ‘First World’ experience BusinessWorld - BusinessWorld Online

Dicerna to License Tekmira LNP Technology in $24.5M Deal - Genetic Engineering and Biotechnology News

Dicerna to License Tekmira LNP Technology in $24.5M Deal Genetic Engineering and Biotechnology News

Megawide unit cues launch of first of five Cavite towers in 2026 - Inquirer.net

Megawide unit cues launch of first of five Cavite towers in 2026 Inquirer.net

PH1 to finish P2-B housing project in Imus in two years - BusinessWorld - BusinessWorld Online

PH1 to finish P2-B housing project in Imus in two years BusinessWorld - BusinessWorld Online

Real-life 'Tatooine' planet orbiting two suns is discovered - South China Morning Post

Real-life 'Tatooine' planet orbiting two suns is discovered South China Morning Post

Megawide’s PH1 breaks ground for 330-unit housing project in Cavite - BusinessWorld - BusinessWorld Online

Megawide’s PH1 breaks ground for 330-unit housing project in Cavite BusinessWorld - BusinessWorld Online

Philips PH1 with Unisoc T310, 4,700mAh battery launched in China - Gizmochina

Philips PH1 with Unisoc T310, 4,700mAh battery launched in China Gizmochina

Top Ph1 Industry Pvt Ltd Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant